Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, first-in-class human clinical trial of MTX-463 evaluating safety, pharmacokinetics, and efficacy in patients with idiopathic pulmonary fibrosis (IPF).

X
Trial Profile

A Phase 2, first-in-class human clinical trial of MTX-463 evaluating safety, pharmacokinetics, and efficacy in patients with idiopathic pulmonary fibrosis (IPF).

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MTX-463 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 16 Jan 2025 New trial record
    • 10 Jan 2025 Mediar Therapeutics announced a global licensing agreement w/ith Eli Lilly and Company to advance MTX-463 into a Phase 2 clinical trial for idiopathic pulmonary fibrosis (IPF). which is designed to evaluate safety, pharmacokinetics, and efficacy in patients. The trial is expected to initiate in the first half of 2025 and will be conducted by Mediar. Following completion of the Phase 2 study, Lilly will have the right to lead all further clinical development and commercialization of the program.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top